Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Roche Holding reported positive Phase II results for its investigational obesity drug CT-388, showing robust efficacy and safety over 48 weeks.
The data indicated significant and clinically meaningful weight loss with strong metabolic benefits and no plateau in effect at 48 weeks.
Roche plans to advance CT-388 into Phase III studies, aiming to compete more directly in the high-demand obesity treatment market.
For investors tracking Roche Holding (SWX:ROG), the CT-388 update adds a fresh angle to a stock that is priced at CHF338.3 and has returned 24.5% over the past year and 35.1% over three years. The move into obesity treatments comes alongside Roche’s existing position in pharmaceuticals and diagnostics, giving shareholders another therapeutic area to watch within the broader portfolio.
The rapid progression of CT-388 into Phase III highlights Roche’s intent to build a presence in obesity treatments, a field attracting strong scientific and commercial attention. Future milestones around trial design, regulatory interactions, and eventual data readouts are likely to be key checkpoints for investors assessing how this program might influence Roche’s long term growth profile.
Stay updated on the most important news stories for Roche Holding by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
SWX:ROG Earnings & Revenue Growth as at Jan 2026
How Roche Holding stacks up against its biggest competitors
The CT-388 Phase II data positions Roche more firmly in the fast-growing obesity drug segment, where Eli Lilly and Novo Nordisk are already established with GLP-1 based therapies. The 22.5% placebo-adjusted weight loss at 48 weeks, combined with metabolic improvements in pre-diabetic participants and a tolerability profile in line with the drug class, gives Roche a clearer product story as it prepares for Phase III and eventual head-to-head comparisons in a crowded field.
For investors who already see Roche as a company leaning on high-value biologics and broader cardiometabolic care, CT-388 adds another late-stage asset that lines up with those themes. Together with Roche’s diagnostics expertise, particularly in areas that could support cardiometabolic monitoring, the obesity program can be viewed as part of a larger push to build more integrated treatment and testing offerings rather than a one-off product bet.
Entry into a large and already active obesity market where Eli Lilly, Novo Nordisk and others have shown strong patient demand for GLP-1 based therapies.
Positive mid-stage data with sustained weight loss, metabolic benefits and low discontinuation rates, which could support Roche’s broader pipeline story if confirmed in Phase III.
Intense competition from established and emerging obesity treatments, including potential future combination regimens that may raise the bar for efficacy and convenience.
Usual late-stage development risks, including the possibility that larger, longer Phase III trials or pricing and reimbursement pressures could limit the commercial impact even if approved.
From here, the key signposts are the design and timing of Phase III trials, any hints on how Roche plans to position CT-388 against existing GLP-1 and dual agonist drugs, and how obesity fits alongside other cardiometabolic and diagnostics initiatives in management commentary. If you want to see how other investors and analysts are thinking about Roche’s longer term story around growth, risk and valuation, take a moment to check community narratives on Roche’s dedicated page.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com